Defunct Company
Total Trials
15
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,166
NCT02181465
Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.
Phase: Phase 2
Role: Lead Sponsor
Start: Oct 31, 1993
Completion: May 31, 1994
NCT02228785
A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer
Start: May 31, 1994
Completion: Not specified
NCT02521649
Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer
Start: Sep 30, 1998
Completion: Jan 31, 2001
NCT02098291
An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
Start: Apr 30, 1999
Completion: Feb 28, 2002
NCT02098239
Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.
Start: Aug 31, 1999
Completion: May 31, 2002
NCT02233712
Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.
NCT02450032
Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer
Start: Feb 29, 2000
Completion: May 31, 2001
NCT02518373
Effect of G17DT in Patients With Stage II/III Colorectal Cancer
Start: Apr 30, 2000
Completion: Feb 28, 2001
NCT02223078
Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.
Start: Jul 31, 2000
Completion: Nov 30, 2001
NCT03200821
An Open Label Study to Evaluate G17DT Compared to Gemcitabine
Phase: Phase 3
Start: Aug 14, 2000
Completion: Sep 19, 2002
NCT00042510
Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer
Start: Aug 31, 2000
Completion: Jul 31, 2004
NCT00044031
Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
Start: Feb 28, 2001
Completion: Oct 31, 2007
NCT02518529
Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients
Completion: Dec 31, 2002
NCT02118064
Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma
Start: Mar 31, 2001
NCT02118077
Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer
Start: Apr 30, 2001